Scynexis (SCYX) Cash from Operations Growth (3y) (2016 - 2026)
Scynexis (SCYX) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.39 Bn | 30.45 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 18.00 Bn | 16.69 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 27.85% |
| 10 | Scynexis | 24.05 Mn | -12.71 Mn | - | 24.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.63% |
| Dec 31, 2025 | 41.06% |
| Sep 30, 2025 | 27.09% |
| Jun 30, 2025 | 26.11% |
| Mar 31, 2025 | 22.42% |
| Dec 31, 2024 | 27.05% |
| Sep 30, 2024 | 26.95% |
| Jun 30, 2024 | 2.44% |
| Mar 31, 2024 | -74.12% |
| Dec 31, 2023 | 22.43% |
| Sep 30, 2023 | 48.25% |
| Jun 30, 2023 | 118.28% |
| Mar 31, 2023 | -10.42% |
| Dec 31, 2022 | -19.22% |
| Sep 30, 2022 | -29.34% |
| Jun 30, 2022 | -33.79% |
| Mar 31, 2022 | -34.98% |
| Dec 31, 2021 | -61.50% |
| Sep 30, 2021 | -39.21% |
| Jun 30, 2021 | -13.98% |